Cyxone was founded in 2015 to develop novel cyclotide drugs for autoimmune and other diseases.
Cyxone has acquired the cyclotide patent rights developed by the Medical University of Vienna and the University Medical Center of Freiburg.
Cyxone’s immediate focus is to bring the lead cyclotide drug, T20K, through a pre-clinical program required for clinical studies in multiple sclerosis.
Cyxone will explore new cyclotides for treatment of other serious diseases in man.
The first documented observatuon on a pharmaceutical effect of a cyclotide is when a Norwegian doctor, Lorents Gran, noted that during labor African women used a medicinal tea made from the leaves of the plant Oldenlandia affinis to induce labor and facilitate childbirth.